We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+14.89%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$84.5M
AUM Growth
+$408K
Cap. Flow
-$6.67M
Cap. Flow %
-7.9%
Top 10 Hldgs %
59.13%
Holding
48
New
14
Increased
9
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$4.79M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.7M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$4.66M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$3.22M
5
BCAX
Bicara Therapeutics
BCAX
+$2.26M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$5.44M
2
ZLAB icon
Zai Lab
ZLAB
+$5.26M
3
PFE icon
Pfizer
PFE
+$4.97M
4
URGN icon
UroGen Pharma
URGN
+$3.22M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$3.18M

Sector Composition

Rank Sector Weight
1 Healthcare 95.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
26
Liquidia Corp
LQDA
$7.11B
$886K 1.05%
+71,071
New +$1.05M
MLTX icon
27
MoonLake Immunotherapeutics
MLTX
$1.64B
$832K 0.98%
17,623
-14,522
-45% -$592K
OCUL icon
28
Ocular Therapeutix
OCUL
$1.96B
$826K 0.98%
88,980
+46,683
+110% +$365K
RCKT icon
29
Rocket Pharmaceuticals
RCKT
$376M
$525K 0.62%
+214,412
New +$1.09M
WVE icon
30
Wave Life Sciences
WVE
$1.12B
$457K 0.54%
+70,242
New +$464K
BMEA icon
31
Biomea Fusion
BMEA
$92.5M
$450K 0.53%
+250,000
New +$482K
KYTX icon
32
Kyverna Therapeutics
KYTX
$453M
$438K 0.52%
142,542
-48,745
-25% -$121K
IPSC icon
33
Century Therapeutics
IPSC
$406M
$259K 0.31%
462,963
– –
SY
34
So-Young International
SY
$169M
$226K 0.27%
+72,936
New +$71.7K
RAPT
35
DELISTED
RAPT Therapeutics
RAPT
$208K 0.25%
+26,034
New +$199K
LSB
36
DELISTED
LakeShore Biopharma
LSB
$31.4K 0.04%
30,792
– –
CAPR icon
37
Capricor Therapeutics
CAPR
$1.13B
– –
-241,192
Closed -$2.29M
CPIX icon
38
CALL
Cumberland Pharmaceuticals
CPIX
$102M
– –
-50,000
Closed -$212K
CRNX icon
39
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-43,613
Closed -$1.46M
LEGN icon
40
Legend Biotech
LEGN
$4.31B
– –
-160,442
Closed -$5.44M
MDGL icon
41
Madrigal Pharmaceuticals
MDGL
$12.8B
– –
-3,815
Closed -$1.26M
PCVX icon
42
Vaxcyte
PCVX
$8.12B
– –
-11,264
Closed -$425K
PFE icon
43
Pfizer
PFE
$143B
– –
-196,164
Closed -$4.97M
SDGR icon
44
Schrodinger
SDGR
$1.14B
– –
-14,114
Closed -$279K
SMMT icon
45
Summit Therapeutics
SMMT
$10.7B
– –
-132,019
Closed -$2.55M
SWTX
46
DELISTED
SpringWorks Therapeutics
SWTX
– –
-54,216
Closed -$2.39M
TSHA icon
47
Taysha Gene Therapies
TSHA
$1.71B
– –
-755,599
Closed -$1.05M
VSTM icon
48
Verastem
VSTM
$530M
– –
-336,363
Closed -$2.03M
1
2

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Superstring Capital Management held 48 positions worth $84.5M, up 0.49% from $84M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Superstring Capital Management withdrew a net $6.67M in Q2 2025, closing 12 positions and reducing 9 holdings. Its most notable exit was Legend Biotech, an estimated $5.44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Jazz Pharmaceuticals worth $4.68M.

  • Superstring Capital Management's largest Q2 2025 buy was Jazz Pharmaceuticals: 44,107 shares worth $4.68M.
  • Superstring Capital Management added most to Soleno Therapeutics in Q2 2025, an estimated $1.07M increase.
  • Superstring Capital Management's biggest Q2 2025 reduction was Zai Lab, cutting an estimated $5.26M.
  • Superstring Capital Management fully exited Legend Biotech in Q2 2025, selling an estimated $5.44M.
  • Superstring Capital Management's ten largest holdings make up 59% of its $84.5M portfolio in Q2 2025.
  • Superstring Capital Management opened 14 new positions and closed 12 in Q2 2025.
  • Superstring Capital Management's portfolio value rose 0.49% quarter-over-quarter to $84.5M.

Based on Superstring Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.